Testing a gut health supplement with immunotherapy after kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery for kidney cancer that showed a clear cell or sarcomatoid component.
- Your cancer stage after surgery is pT2 (high grade), pT3-pT4, or cancer that has spread to lymph nodes or other parts of the body but was removed with no signs of disease left.
- You have not received immunotherapy (like pembrolizumab, nivolumab, or ipilimumab) for your kidney cancer before.
- You are generally well enough to carry out daily activities (ECOG score less than 2).
- You are willing to avoid probiotics, prebiotics, yogurt, and similar foods for 2 weeks before and during treatment.
- You do not have an active autoimmune disease or a condition requiring high-dose steroids (more than 10 mg of prednisone per day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
This trial tests whether the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. It is for people with a less common type of kidney cancer called non-clear cell renal cell carcinoma that was at a higher stage or had spread but was fully removed.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.